Revagenix
Latest round
- Series B
Last raised
- Jan 2024
Total raised
- Undisclosed
Investors
- 2
About Revagenix
Based in California, US, and founded in 2019, Revagenix, Inc. operates as a biopharmaceutical company that offers antimicrobial treatments for infection types including cUTI, HABP/VABP, and neonatal sepsis/BSI. In January 2024, Revagenix, Inc. Revagenix's primary focus lies in advancing a proprietary pipeline of highly differentiated antibiotic programs. These programs offer solutions to combat drug-resistant infections. The company's commitment to research and development is reflected in its holistic approach to understanding the complexities of the anti-infective landscape, driving the creation of novel therapeutic solutions.
Who invested in Revagenix
2 investors across 1 round
See all investors in Revagenix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jan 5, 2024
Amount
Undisclosed
Investors
Questions about Revagenix
Who invested in Revagenix?
Revagenix has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Revagenix raised?
Revagenix has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Revagenix last raise money?
Revagenix's most recent round on record is a Series B, in Jan 2024.
What does Revagenix do?
Based in California, US, and founded in 2019, Revagenix, Inc.
Where is Revagenix headquartered?
Revagenix is headquartered in San Mateo, US.
Which VCs invest in companies like Revagenix?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Revagenix's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Revagenix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.